Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Sirtex Doses First Patient in China Trial of Microsphere Radiation Therapy

publication date: Oct 13, 2021

Sirtex Medical, a division of China Grand Pharma and Healthcare, started a China trial of its selective internal radiation therapy in patients with hepatocellular carcinoma (HCC). One year ago, Sirtex filed an NDA in China for its SIR-Spheres® Y-90 resin microspheres, a targeted radiation therapy, for liver metastases from colorectal cancer. The Y-90 resin microspheres are designed to accumulate in the liver, where they deliver a 40-times larger dose of radiation without affecting normal tissue. In 2018, China's CDH Holding paid $1.9 billion to acquire Sirtex. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here